{"protocolSection":{"identificationModule":{"nctId":"NCT00119626","orgStudyIdInfo":{"id":"SA-NXY-0006"},"secondaryIdInfos":[{"id":"0006"},{"id":"SAINT I"}],"organization":{"fullName":"AstraZeneca","class":"INDUSTRY"},"briefTitle":"Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke","officialTitle":"SAINT I (Stroke - Acute Ischemic - NXY Treatment) A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke."},"statusModule":{"statusVerifiedDate":"2010-11","overallStatus":"COMPLETED","startDateStruct":{"date":"2003-06"},"primaryCompletionDateStruct":{"date":"2005-02","type":"ACTUAL"},"completionDateStruct":{"date":"2005-02","type":"ACTUAL"},"studyFirstSubmitDate":"2005-07-06","studyFirstSubmitQcDate":"2005-07-13","studyFirstPostDateStruct":{"date":"2005-07-14","type":"ESTIMATED"},"lastUpdateSubmitDate":"2010-11-10","lastUpdatePostDateStruct":{"date":"2010-11-15","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"leadSponsor":{"name":"AstraZeneca","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"This study will determine if NXY-059 will reduce functional disability from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strength and coordination."},"conditionsModule":{"conditions":["Cerebral Stroke","Ischemic Attack, Transient"],"keywords":["Stroke, Acute","Cerebrovascular Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE"}},"enrollmentInfo":{"count":1700}},"armsInterventionsModule":{"interventions":[{"type":"DRUG","name":"NXY-059"}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Global disability on modified Rankin scale at 90 days."}],"secondaryOutcomes":[{"measure":"NIH stroke scale (termed \"co-primary\" in study protocol), Barthel Index, Stroke Impact Scale, EQ-5D all at 90 days, Safety outcomes."}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males and females\n* Acute ischemic stroke with limb weakness, onset of symptoms within 6 hours\n* Full functional independence prior to the present stroke\n\nExclusion Criteria:\n\n* Unconsciousness\n* Subjects who are unlikely to complete the infusion of investigational product and/or are unlikely to undergo active medical management during that period due to a severe clinical condition\n* Severe illness with life expectancy less than 6 months\n* Known severe kidney disorder\n* Current known alcohol or illicit drug abuse or dependence\n* Pregnant or breast-feeding\n* Treatment with acetazolamide and methotrexate is not permitted during the infusion\n* Participation in a previous clinical study within 30 days","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"AstraZeneca NXY-059 Medical Science Director, MD","affiliation":"AstraZeneca","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Research Site","city":"Södertälje","country":"Sweden","geoPoint":{"lat":59.19554,"lon":17.62525}},{"facility":"Research Site","city":"Glasgow","country":"United Kingdom","geoPoint":{"lat":55.86515,"lon":-4.25763}}]},"referencesModule":{"references":[{"pmid":"16467546","type":"RESULT","citation":"Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW; Stroke-Acute Ischemic NXY Treatment (SAINT I) Trial Investigators. NXY-059 for acute ischemic stroke. N Engl J Med. 2006 Feb 9;354(6):588-600. doi: 10.1056/NEJMoa052980."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000002546","term":"Ischemic Attack, Transient"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000002545","term":"Brain Ischemia"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","relevance":"LOW"},{"id":"M5485","name":"Ischemic Attack, Transient","asFound":"Ischemic Attack, Transient","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000120851","term":"Disufenton sodium"}],"ancestors":[{"id":"D000000975","term":"Antioxidants"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000020011","term":"Protective Agents"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M232497","name":"Disufenton sodium","asFound":"DS-1040b","relevance":"HIGH"},{"id":"M3982","name":"Antioxidants","relevance":"LOW"},{"id":"M21559","name":"Protective Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}